Litcius/Paper detail

Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests

Marianna Traugott, Stephan W. Aberle, Judith H. Aberle, Hannah Griebler, Mario Karolyi, Erich Pawelka, Elisabeth Puchhammer‐Stöckl, Alexander Zoufaly, Lukas Weseslindtner

2020The Journal of Infectious Diseases72 citationsDOIOpen Access PDF

Abstract

We comparatively assessed sensitivities and specificities of 4 commercial enzyme-linked immunosorbent assays (ELISAs) and 2 rapid tests in 77 patients with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection, grouped by interval since symptom onset. Although test sensitivities were low (<40%) within the first 5 days after disease onset, immunoglobulin (Ig) M, IgA, and total antibody ELISAs increased in sensitivity to >80% between days 6 and 10 after symptom onset. The evaluated tests (including IgG and rapid tests) provided positive results in all patients at or after the 11th day after onset of disease. The specificities of the ELISAs were 83% (IgA), 98% (IgG), and 97% (IgM and total antibody).

Topics & Concepts

AntibodyImmunologyMedicineCoronavirusVirologyImmunoglobulin GRespiratory diseaseRespiratory systemPolymerase chain reactionSerologyImmunoglobulin MEnzymeBiologyDiseaseCoronavirus disease 2019 (COVID-19)Internal medicineInfectious disease (medical specialty)GeneLungBiochemistrySARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies